



# 2020 Dietary Guidelines Advisory Committee: Discussion

*Facilitated by*

*Barbara Schneeman, PhD, Chair and  
Ronald Kleinman, MD, Vice Chair*

---



# 2020 Dietary Guidelines Advisory Committee

## *Subcommittee Structure and Membership*

- The purpose of the subcommittees is to review evidence and provide advice to the parent Committee
- Six topic area subcommittees
- One cross-cutting working group
- Subcommittee size varies based on expected workload
- Members serve on no more than two subcommittees



# 2020 Dietary Guidelines Advisory Committee

## *Subcommittee Structure and Membership*

<b>Dietary Patterns</b>	<b>Pregnancy and Lactation</b>	<b>Birth to 24 Months</b>	<b>Beverages and Added Sugars</b>	<b>Dietary Fats and Seafood</b>	<b>Frequency of Eating</b>
Chair: Carol Boushey	Chair: Sharon Donovan	Chair: Kay Dewey	Chair: Elizabeth Mayer-Davis	Chair: Linda Snetselaar	Chair: Steven Heymsfield
Chair/Vice Chair rep: Barbara Schneeman	Chair/Vice Chair rep: Ron Kleinman	Chair/Vice Chair rep: Ron Kleinman	Chair/Vice Chair rep: Barbara Schneeman	Chair/Vice Chair rep: Barbara Schneeman	Chair/Vice Chair rep: Ron Kleinman
Members: Jamy Ard Lydia Bazzano Steven Heymsfield Elizabeth Mayer-Davis Joan Sabate Linda Snetselaar Linda Van Horn	Members: Kay Dewey Rachel Novotny Jamie Stang Elsie Taveras	Members: Lydia Bazzano Teresa Davis Sharon Donovan Elsie Taveras	Members: Heather Leidy Richard Mattes Timothy Naimi Rachel Novotny	Members: Regan Bailey Joan Sabate Linda Van Horn	Members: Carol Boushey Heather Leidy Richard Mattes

<b>Data Analysis and Food Pattern Modeling – Cross-Cutting Working Group</b>	Chair: Regan Bailey  Chair/Vice Chair rep: Barbara Schneeman	Members: Jamy Ard Teresa Davis Timothy Naimi Jamie Stang
--	---	--

# Several systematic reviews address neurocognitive and cancer outcomes

- 10 systematic review questions address the relationship between diet and neurocognitive outcomes.
- 3 systematic review questions address the relationship between diet and risk of certain types of cancers.
- The questions will be addressed by several subcommittees, so it is desirable for the subcommittees to approach this outcome similarly across the reviews.

# Background on NESR neurocognitive and cancer outcomes

Discuss the neurocognitive and cancer outcomes previously considered in NESR systematic reviews :

- Are additional outcomes warranted?
- Are some outcomes no longer relevant to include?

Factors to consider when selecting and prioritizing outcomes to include:

- Outcomes included in NESR systematic reviews are typically those of public health significance, which promote population health or well-being, and/or reduce the significant burden of avoidable disease.
- Outcomes may include endpoint and/or intermediate outcomes.
- Generally, for many outcomes, validated biomarkers are included, but emerging biomarkers are excluded.

# Neurocognitive outcomes considered in previous NESR systematic reviews

	Age	Outcomes considered previously
<b>Developmental milestones, including neurocognitive development</b>	Birth to ? Years	<ul style="list-style-type: none"> <li>• Developmental milestone achievement (e.g., age first crawled)</li> <li>• Scores on developmental indices/scales (e.g., ASQ, BSID)</li> </ul>
<b>Neurocognitive development</b>	Birth to 18 years	<ul style="list-style-type: none"> <li>• Cognitive development (e.g., academic performance, IQ)</li> <li>• Executive function (e.g., inhibitory control, working memory, planning, goal-directed behavior)</li> <li>• Motor development</li> <li>• Communication development</li> <li>• Social-emotional development</li> <li>• Neurological development</li> <li>• Incidence and prevalence of anxiety</li> <li>• Incidence and prevalence of depression</li> </ul>
<b>Neurocognitive health</b>	18 years and older	<ul style="list-style-type: none"> <li>• Depression</li> <li>• Dementia</li> <li>• Cognitive impairment</li> <li>• Alzheimer's Disease</li> </ul>



# Cancer outcomes considered in previous NESR systematic reviews

Previous NESR systematic reviews considered the 4 most common cancers in the US:

- Breast cancer
- Colorectal cancer
- Lung cancer
- Prostate cancer

